Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Benenati, J; Shlansky-Goldberg, R; Meglin, A; Seidl, E
   Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab - The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL
   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
   
   J. Benenati et al., "Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab - The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL", J VAS INT R, 12(7), 2001, pp. 795-805
2. Marder, VJ
   Thrombolytic therapy: 2001
   BLOOD REVIEWS
   
   V.J. Marder, "Thrombolytic therapy: 2001", BLOOD REV, 15(3), 2001, pp. 143-157
3. Sinnaeve, P; Van de Werf, F
   Thrombolytic therapy - State of the art
   THROMBOSIS RESEARCH
   
   P. Sinnaeve e F. Van de Werf, "Thrombolytic therapy - State of the art", THROMB RES, 103, 2001, pp. S71-S79
4. Armstrong, PW; Collen, D
   Fibrinolysis for acute myocardial infarction - Current status and new horizons for pharmacological reperfusion, Part 1
   CIRCULATION
   
   P.W. Armstrong e D. Collen, "Fibrinolysis for acute myocardial infarction - Current status and new horizons for pharmacological reperfusion, Part 1", CIRCULATION, 103(23), 2001, pp. 2862-2866
5. Collen, D; Lijnen, HR
   Recent developments in thrombolytic therapy
   FIBRINOLYSIS & PROTEOLYSIS
   
   D. Collen e H.R. Lijnen, "Recent developments in thrombolytic therapy", FIBRINOL PR, 14(2-3), 2000, pp. 66-72
6. Modi, NB; Fox, NL; Clow, FW; Tanswell, P; Cannon, CP; Van de Werf, F; Braunwald, E
   Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction
   JOURNAL OF CLINICAL PHARMACOLOGY
   
   N.B. Modi et al., "Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction", J CLIN PHAR, 40(5), 2000, pp. 508-515
7. Verstraete, M
   Third-generation thrombolytic drugs
   AMERICAN JOURNAL OF MEDICINE
   
   M. Verstraete, "Third-generation thrombolytic drugs", AM J MED, 109(1), 2000, pp. 52-58
8. Breuer, M; Schutz, A; Gansera, B; Eichinger, W; Weingartner, J; Kemkes, B
   Intraoperative local fibrinolysis as emergency therapy after early coronary artery bypass thrombosis
   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
   
   M. Breuer et al., "Intraoperative local fibrinolysis as emergency therapy after early coronary artery bypass thrombosis", EUR J CAR-T, 15(3), 1999, pp. 266-270
9. Martin, U; Kaufmann, B; Neugebauer, G
   Current clinical use of reteplase for thrombolysis - A pharmacokinetic-pharmacodynamic perspective
   CLINICAL PHARMACOKINETICS
   
   U. Martin et al., "Current clinical use of reteplase for thrombolysis - A pharmacokinetic-pharmacodynamic perspective", CLIN PHARMA, 36(4), 1999, pp. 265-276
10. EPPLER S; SENN T; GILKERSON E; MODI NB
    PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR FOLLOWING INTRAVENOUS ADMINISTRATION IN RABBITS - A COMPARISON OF 3 DOSING REGIMENS
    Biopharmaceutics & drug disposition
    
    S. Eppler et al., "PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR FOLLOWING INTRAVENOUS ADMINISTRATION IN RABBITS - A COMPARISON OF 3 DOSING REGIMENS", Biopharmaceutics & drug disposition, 19(1), 1998, pp. 31-38
11. AYLWARD P
    CAN WE IMPROVE ON FRONT-LOADED ALTEPLASE (R-TPA)
    Australian and New Zealand Journal of Medicine
    
    P. Aylward, "CAN WE IMPROVE ON FRONT-LOADED ALTEPLASE (R-TPA)", Australian and New Zealand Journal of Medicine, 28(4), 1998, pp. 511-513
12. BODE C; PETER K; NORDT TK; RUEF J; SMALLING RW; KUBLER W
    PHARMACOLOGY AND CLINICAL EFFICACY OF RETEPLASE
    Fibrinolysis & proteolysis
    
    C. Bode et al., "PHARMACOLOGY AND CLINICAL EFFICACY OF RETEPLASE", Fibrinolysis & proteolysis, 11, 1997, pp. 29-33
13. SMALLING RW
    A FRESH LOOK AT THE MOLECULAR PHARMACOLOGY OF PLASMINOGEN ACTIVATORS - FROM THEORY TO TEST-TUBE TO CLINICAL OUTCOMES
    American journal of health-system pharmacy
    
    R.W. Smalling, "A FRESH LOOK AT THE MOLECULAR PHARMACOLOGY OF PLASMINOGEN ACTIVATORS - FROM THEORY TO TEST-TUBE TO CLINICAL OUTCOMES", American journal of health-system pharmacy, 54, 1997, pp. 17-22
14. SMALLING RW
    PHARMACOLOGICAL AND CLINICAL IMPACT OF THE UNIQUE MOLECULAR-STRUCTUREOF A NEW PLASMINOGEN-ACTIVATOR
    European heart journal
    
    R.W. Smalling, "PHARMACOLOGICAL AND CLINICAL IMPACT OF THE UNIQUE MOLECULAR-STRUCTUREOF A NEW PLASMINOGEN-ACTIVATOR", European heart journal, 18, 1997, pp. 11-16
15. BODE C; PETER K; MOSER M; SMALLING RW; WEAVER WD
    CLINICAL-TRIAL RESULTS WITH A NEW PLASMINOGEN-ACTIVATOR
    European heart journal
    
    C. Bode et al., "CLINICAL-TRIAL RESULTS WITH A NEW PLASMINOGEN-ACTIVATOR", European heart journal, 18, 1997, pp. 17-21
16. HAMPTON JR
    THE CONCEPT OF EQUIVALENCE AND ITS APPLICATION TO THE ASSESSMENT OF THROMBOLYTIC EFFECTS
    European heart journal
    
    J.R. Hampton, "THE CONCEPT OF EQUIVALENCE AND ITS APPLICATION TO THE ASSESSMENT OF THROMBOLYTIC EFFECTS", European heart journal, 18, 1997, pp. 22-27
17. HANNA GP; SMALLING RW
    RETEPLASE, A NEW 3RD-GENERATION THROMBOLYTIC AGENT
    Medicamentos de actualidad
    
    G.P. Hanna e R.W. Smalling, "RETEPLASE, A NEW 3RD-GENERATION THROMBOLYTIC AGENT", Medicamentos de actualidad, 33(9), 1997, pp. 627-631
18. FISCHER S
    THE MOLECULAR DESIGN OF RETEPLASE
    Medicamentos de actualidad
    
    S. Fischer, "THE MOLECULAR DESIGN OF RETEPLASE", Medicamentos de actualidad, 33(9), 1997, pp. 641-648
19. BODE C; MOSER M; RUEF J; NORDT T; PETER K; KUBLER W; SMALLING RW
    CLINICAL-STUDIES WITH RETEPLASE
    Medicamentos de actualidad
    
    C. Bode et al., "CLINICAL-STUDIES WITH RETEPLASE", Medicamentos de actualidad, 33(9), 1997, pp. 649-653
20. BODE C; GULBA D; HUBER K; RUNGE MS
    NEW APPROACHES IN PLASMINOGEN-ACTIVATOR THERAPY
    Annals of hematology
    
    C. Bode et al., "NEW APPROACHES IN PLASMINOGEN-ACTIVATOR THERAPY", Annals of hematology, 73, 1996, pp. 1-7
21. NOBLE S; MCTAVISH D
    RETEPLASE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL EFFICACY IN THE MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION
    Drugs
    
    S. Noble e D. Mctavish, "RETEPLASE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL EFFICACY IN THE MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION", Drugs, 52(4), 1996, pp. 589-605
22. MARTIN U; DORGE L; FISCHER S
    COMPARISON OF DESULFATOHIRUDIN (REVASC) AND HEPARIN AS ADJUNCTS TO THROMBOLYTIC THERAPY WITH RETEPLASE IN A CANINE MODEL OF CORONARY-THROMBOSIS
    British Journal of Pharmacology
    
    U. Martin et al., "COMPARISON OF DESULFATOHIRUDIN (REVASC) AND HEPARIN AS ADJUNCTS TO THROMBOLYTIC THERAPY WITH RETEPLASE IN A CANINE MODEL OF CORONARY-THROMBOSIS", British Journal of Pharmacology, 118(2), 1996, pp. 271-276
23. SMALLING RW
    MOLECULAR-BIOLOGY OF PLASMINOGEN ACTIVATORS - WHAT ARE THE CLINICAL IMPLICATIONS OF DRUG DESIGN
    The American journal of cardiology
    
    R.W. Smalling, "MOLECULAR-BIOLOGY OF PLASMINOGEN ACTIVATORS - WHAT ARE THE CLINICAL IMPLICATIONS OF DRUG DESIGN", The American journal of cardiology, 78, 1996, pp. 2-7
24. BODE C; NORDT TK; PETER K; SMALLING RW; RUNGE MS; KUBLER W
    PATENCY TRIALS WITH RETEPLASE (R-PA) - WHAT DO THEY TELL US
    The American journal of cardiology
    
    C. Bode et al., "PATENCY TRIALS WITH RETEPLASE (R-PA) - WHAT DO THEY TELL US", The American journal of cardiology, 78, 1996, pp. 16-19
25. BODE C; KOHLER B; SMALLING RW; RUNGE MS
    RETEPLASE (R-PA) - A NOVEL RECOMBINANT PLASMINOGEN-ACTIVATOR
    Fibrinolysis
    
    C. Bode et al., "RETEPLASE (R-PA) - A NOVEL RECOMBINANT PLASMINOGEN-ACTIVATOR", Fibrinolysis, 9, 1995, pp. 97-99
26. RIJKEN DC; GROENEVELD E; BARRETTBERGSHOEFF MM
    IN-VITRO STABILITY OF A TISSUE-TYPE PLASMINOGEN-ACTIVATOR MUTANT, BM-06.022, IN HUMAN PLASMA
    Thrombosis and haemostasis
    
    D.C. Rijken et al., "IN-VITRO STABILITY OF A TISSUE-TYPE PLASMINOGEN-ACTIVATOR MUTANT, BM-06.022, IN HUMAN PLASMA", Thrombosis and haemostasis, 72(6), 1994, pp. 906-911